Appeal No. 2003-0913 3
Application No. 09/277,049
(d) optionally powdering the crystalline meloxicam-meglumin salt
monohydrate and intimately mixing the crystalline meloxicam-
meglumin salt monohydrate with a conventional powdered excipient
or carrier to obtain a pharmaceutical mixture; and
(e) compressing the pharmaceutical mixture from step (d) directly into
tablets with no granulation of the powder.
THE REFERENCES OF RECORD
As evidence of obviousness, the examiner relies upon the following references:
Trummlitz et al. 4,233,299 Nov. 11, 1980
Luger et al. (Luger), “Structure and physicochemical properties of meloxicam, a new
NSAID”, European Journal of Pharmaceutical Sciences, 1996, Vol. 4, pp. 175-187.
Murray, Lori (Editor), “Physicians’ Desk Reference”, 56th ed., © 2002, pp. 30 and 1054.
Cited for state of the art, not to be construed as a new prior art.
Gennaro, A.R. (Editor) “Remington’s pharmaceutical Sciences”, 18th ed., © 1990, pp. 1644-
1646. Cited for state of the art, not to be construed as a new prior art.
THE REJECTIONS
Claims 1, 4 and 14 stand rejected under 35 U.S.C. § 112, second paragraph, as
being indefinite for failing to particularly point out and distinctly claim the subject matter
which appellants regard as the invention.
Claims 6 through 19 stand rejected under 35 U.S.C. § 112, first paragraph, as
containing subject matter which was not described in the specification in such a way as to
enable one skilled in the art to which it pertains, or with which it is most nearly connected to
make and/or use the invention.
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 Next
Last modified: November 3, 2007